JAMA Network Home
Sign In
Research Letter

Pediatric JAK Inhibitor Use and Height in Common Inflammatory Diseases

JAMA Dermatology 10.1001/jamadermatol.2025.3934

October 29, 2025 at 11:00 AM EDT

Read the full article

This cohort study evaluates the association between Janus kinase (JAK) inhibitor use and height in pediatric patients with atopic dermatitis, juvenile idiopathic arthritis, and inflammatory bowel disease.

Corresponding Author: John S. Barbieri, MD, MBA, Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, 221 Longwood Ave, Boston, MA 02115 (jbarbieri@bwh.harvard.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2025.3934?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=102925

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks